BDX Becton, Dickinson and Company logo

BDX Becton, Dickinson and Company

Healthcare
$147.63+0.94%ClosedMarket Cap: $53.49B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

31.80

PEG

18.31

P/B

1.72

P/S

2.50

EV/EBITDA

16.80

DCF Value

$1,124.36

FCF Yield

5.9%

Div Yield

2.4%

Margins & Returns

Gross Margin

46.5%

Operating Margin

10.6%

Net Margin

5.3%

ROE

4.5%

ROA

2.2%

ROIC

4.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$4.71B$-311.0M$
Q1 null$5.25B$382.0M$
Q4 null$5.89B$493.0M$
FY null$21.84B$1.68B$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$173.19

Target (Median)

$168.01

Target Range

$159.00 - $204.00

1 Strong Buy6 Buy9 Hold0 Sell0 Strong Sell
BarclaysOverweight
2026-05-11
Wells FargoEqual Weight
2026-05-08
TD CowenHold
2026-05-04
Piper SandlerNeutral
2026-04-17
Argus ResearchBuy
2026-03-23

Trading Activity

Insider Trades

View All
Roque Vitorofficer: EVP & Chief Financial Officer
SellFri May 08
Huffines Robert Lutherdirector
SellFri May 08
Byington Carrie Ldirector
SellFri May 08
Feld Michaelofficer: EVP, Chief Revenue Officer
SellTue Apr 28
Neal Shana Carolofficer: EVP and Chief People Officer
SellMon Apr 06

Congress Trades

View All
Kevin HernSell
Mon Apr 06

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

0.28

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Peers